We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.32 | 0.65% | 49.33 | 49.00 | 49.44 | 49.45 | 48.98 | 49.25 | 1,187,885 | 00:59:59 |
By Cristina Roca
Sanofi SA (SAN.FR) said Thursday that it hired the head of Bayer AG's (BAYN.XE) pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.
The French pharmaceutical group named Dieter Weinand to head the Primary Care unit, and also made him executive vice president, effective Nov. 1. Mr. Weinand joins Sanofi from Bayer, where he was a member of the board of management, the company said.
The Primary Care unit will combine the Diabetes and Cardiovascular unit with Established Products, which is currently part of a different division, Sanofi said. The head of the Diabetes and Cardiovascular unit, Stefan Oelrich, will leave Sanofi to join Bayer as a member of the German company's board of management and head of the pharmaceuticals division, effective Nov. 1, Sanofi said.
Sanofi said it also appointed Olivier Charmeil to lead its newly-created unit called China and Emerging Markets. Mr. Charmeil is currently head of another Sanofi unit and will remain on the Executive Committee, Sanofi said.
Write to Cristina Roca at cristina.roca@dowjones.com
(END) Dow Jones Newswires
September 13, 2018 07:14 ET (11:14 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions